-
Je něco špatně v tomto záznamu ?
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
I. Chau, JO. Park, BY. Ryoo, CJ. Yen, R. Poon, D. Pastorelli, JF. Blanc, M. Kudo, T. Pfiffer, E. Hatano, HC. Chung, K. Kopeckova, JM. Phelip, G. Brandi, S. Ohkawa, CP. Li, T. Okusaka, Y. Hsu, PB. Abada, AX. Zhu,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1947 do Před 1 rokem
Freely Accessible Journals
od 1947 do Před 1 rokem
PubMed Central
od 1947 do Před 1 rokem
Europe PubMed Central
od 1947 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1947-01-01
Open Access Digital Library
od 1999-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- alfa-fetoproteiny metabolismus MeSH
- dospělí MeSH
- hepatocelulární karcinom krev diagnostické zobrazování farmakoterapie patologie MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- nádory jater krev diagnostické zobrazování farmakoterapie patologie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- rentgendiagnostika metody MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. METHODS: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. RESULTS: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53; P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). CONCLUSIONS: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
Department of Medical Oncology Instituto do Câncer do Estado de São Paulo São Paulo 01246 000 Brazil
Department of Medicine Harvard Medical School Massachusetts General Hospital Boston MA 02114 USA
Department of Medicine Royal Marsden Hospital Sutton Surrey SM2 5PT UK
Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul 05505 Korea
Department of Oncology Santa Maria del Prato Hospital Feltre 32032 Italy
Department of Surgery Graduate School of Medicine Kyoto University Kyoto 606 8507 Japan
Departmentof Surgery The University of Hong Kong Pokfulam Hong Kong
Division of Hepatobiliary and Pancreatic Oncology Kanagawa Cancer Center Yokohama 241 0815 Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035212
- 003
- CZ-PrNML
- 005
- 20191011090031.0
- 007
- ta
- 008
- 191007s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41416-018-0103-0 $2 doi
- 035 __
- $a (PubMed)29808014
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chau, Ian $u Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK. Ian.Chau@rmh.nhs.uk.
- 245 10
- $a Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study / $c I. Chau, JO. Park, BY. Ryoo, CJ. Yen, R. Poon, D. Pastorelli, JF. Blanc, M. Kudo, T. Pfiffer, E. Hatano, HC. Chung, K. Kopeckova, JM. Phelip, G. Brandi, S. Ohkawa, CP. Li, T. Okusaka, Y. Hsu, PB. Abada, AX. Zhu,
- 520 9_
- $a BACKGROUND: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. METHODS: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. RESULTS: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53; P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). CONCLUSIONS: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
- 650 _2
- $a hepatocelulární karcinom $x krev $x diagnostické zobrazování $x farmakoterapie $x patologie $7 D006528
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a nádory jater $x krev $x diagnostické zobrazování $x farmakoterapie $x patologie $7 D008113
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rentgendiagnostika $x metody $7 D011859
- 650 _2
- $a alfa-fetoproteiny $x metabolismus $7 D000509
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Park, Joon Oh $u Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea.
- 700 1_
- $a Ryoo, Baek-Yeol $u Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
- 700 1_
- $a Yen, Chia-Jui $u Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
- 700 1_
- $a Poon, Ronnie $u Departmentof Surgery, The University of Hong Kong, Pokfulam, Hong Kong.
- 700 1_
- $a Pastorelli, Davide $u Department of Oncology, Santa Maria del Prato Hospital, Feltre (Belluno), 32032, Italy.
- 700 1_
- $a Blanc, Jean-Frédéric $u Department of Hepato-Gastroenterology and Medical Oncology, CHU de Bordeaux, Hôpital Haut-Lévêque, 33604, Pessac, France.
- 700 1_
- $a Kudo, Masatoshi $u Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, 589-8511, Japan.
- 700 1_
- $a Pfiffer, Tulio $u Department of Medical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, 01246-000, Brazil.
- 700 1_
- $a Hatano, Etsuro $u Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
- 700 1_
- $a Chung, Hyun Cheol $u Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Korea.
- 700 1_
- $a Kopeckova, Katerina $u Department of Oncology, University Hospital Motol, 2nd Faculty of Medicine of Charles University, 150 00, Praha, Czech Republic.
- 700 1_
- $a Phelip, Jean-Marc $u Department of Gastroenterology and Digestive Oncology, University Hospital of St Etienne, 42100, Saint Etienne, France.
- 700 1_
- $a Brandi, Giovanni $u Department of Experimental, Diagnostic and Specialty Medicine, University Hospital S. Orsola, 40138, Bologna, Italy.
- 700 1_
- $a Ohkawa, Shinichi $u Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, 241-0815, Japan.
- 700 1_
- $a Li, Chung-Pin $u Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan. National Yang-Ming University School of Medicine, Taipei, 112, Taiwan.
- 700 1_
- $a Okusaka, Takuji $u Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
- 700 1_
- $a Hsu, Yanzhi $u Eli Lilly and Company, New York, NY, 10016, USA.
- 700 1_
- $a Abada, Paolo B $u Eli Lilly and Company, Indianapolis, IN, 46285, USA.
- 700 1_
- $a Zhu, Andrew X $u Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, 02114, USA.
- 773 0_
- $w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 119, č. 1 (2018), s. 19-26
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29808014 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191011090451 $b ABA008
- 999 __
- $a ok $b bmc $g 1451872 $s 1073762
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 119 $c 1 $d 19-26 $e 20180529 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
- LZP __
- $a Pubmed-20191007
